TARA

Protara Therapeutics, Inc. [TARA] Stock Forecast

Q: What is Protara Therapeutics, Inc. stock symbol ?

Protara Therapeutics, Inc. is a US stock, located in New york of Ny and trading under the symbol TARA

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

TARA Stock Summary

TARA has more than 2 years of cash runway (26 months)

Top 10 Correlated ETFs

TARA

Top 10 Correlated Stocks

TARA

In the News

08:00 22 Mar 2023 TARA

Protara Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following upcoming investor conferences:

08:00 22 Mar 2023 TARA

Protara Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day

NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks Oncology Day on Thursday, February 9, 2023 at 11:20 am ET in New York, New York.

11:00 22 Mar 2023 TARA

Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market

In October 2021, I made a big call on Longeveron (NASDAQ: LGVN ) stock, a biotech firm working on a promising Alzheimer's therapy.

07:14 22 Mar 2023 TARA

Executives Buy Around $35M Of 4 Penny Stocks: Nextdoor, GreenLight Biosciences And More

The Dow Jones jumped by around 150 points on Monday. Investors, meanwhile, focused on some notable insider trades.

11:17 22 Mar 2023 TARA

Can Protara Therapeutics (TARA) Climb 680% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 680.4% in Protara Therapeutics (TARA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

08:00 22 Mar 2023 TARA

Protara Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in fireside chats at two upcoming virtual conferences:

08:00 22 Mar 2023 TARA

Protara Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference

NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at the H.C. Wainwright BioConnect Virtual Conference being held from January 10-13, 2022.

05:57 22 Mar 2023 TARA

TARA Stock: Why The Price Increased This Past Week

The stock price of Protara Therapeutics Inc (NASDAQ: TARA) increased by over 5% during intraday trading. This is why it happened.

10:26 22 Mar 2023 TARA

Biopharma Stock Skyrockets on FDA Approval

Biopharmaceutical stock Protara Therapeutics Inc (NASDAQ:TARA) is surging today, up 11.9% to trade at $7.55 at last check.

09:43 22 Mar 2023 TARA

Why Protara Therapeutics Stock Is Rising Today

Protara Therapeutics Inc (NASDAQ: TARA) is trading higher Tuesday after the company announced FDA clearance of the Investigational New Drug application for TARA-002 for the treatment of non-muscle invasive bladder cancer. Protara Therapeutics expects to begin a Phase 1 clinical trial of TARA-002 in adults with high-grade non-muscle invasive bladder cancer by the end of 2021.

TARA Financial details

Company Rating

Neutral

Market Cap

39.35M

Income

-65.95M

Revenue

Book val./share

9.07

Cash/share

7.49

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

03 May 2023

P/E

-1.12

Forward P/E

PEG

1.09

P/S

P/B

0.3

P/C

0.5

P/FCF

-1.47

Quick Ratio

26.06

Current Ratio

26.59

Debt / Equity

0.11

LT Debt / Equity

0.05

EPS (TTM)

-5.86

EPS next Y

EPS next Q

EPS this Y

-10.29%

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

408.82%

SMA20

SMA50

SMA100

Inst Own

48.63%

Inst Trans

-1.69%

ROA

-25%

ROE

-25%

ROC

-0.26%

Gross Margin

Oper. Margin

Profit Margin

Payout

Shs Outstand

11.31M

Shs Float

5.97M

Target Price

52W Range

2.378-5.71

52W High

-25.8%

52W Low

+85.5%

RSI

Rel Volume

6.75

Avg Volume

21.25K

Volume

143.31K

Perf Week

34.42%

Perf Month

9.12%

Perf Quarter

3.92%

Perf Half Y

-1.59%

Beta

1.56785

Volatility

0.26%, 0.3%

Prev Close

Price

3.71

Change

2.49%

TARA Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
Revenue per share	0	0	0	0	0
Net income per share	-3.9	-2.57	-4.7	-4.21	-5.86
Operating cash flow per share	-4.37	-2.68	-3.24	-3.07	-2.35
Free cash flow per share	-4.39	-2.68	-3.36	-3.12	-2.36
Cash per share	4.11	1.06	23.31	8.12	7.49
Book value per share	3.84	1.09	27.54	14.41	9.07
Tangible book value per share	3.84	1.09	23.46	11.79	9.07
Share holders equity per share	3.84	1.09	27.54	14.41	9.07
Interest debt per share	0	0	0.01	0.8	0.57
Market cap	483.07M	95.84M	175.13M	75.82M	30.18M
Enterprise value	463.7M	89.66M	7.62M	47.33M	12.43M
P/E ratio	-23.3	-6.39	-5.15	-1.6	-0.46
Price to sales ratio	0	0	0	0	0
POCF ratio	-20.79	-6.13	-7.48	-2.2	-1.14
PFCF ratio	-20.69	-6.12	-7.21	-2.16	-1.14
P/B Ratio	23.63	14.99	0.88	0.47	0.3
PTB ratio	23.63	14.99	0.88	0.47	0.3
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-22.49	-6.09	-0.23	-1.04	-0.19
EV to operating cash flow	-19.96	-5.73	-0.33	-1.37	-0.47
EV to free cash flow	-19.86	-5.72	-0.31	-1.35	-0.47
Earnings yield	-0.04	-0.16	-0.19	-0.62	-2.19
Free cash flow yield	-0.05	-0.16	-0.14	-0.46	-0.88
Debt to equity	0.15	0.09	0.02	0.07	0.11
Debt to assets	0.13	0.08	0.02	0.06	0.1
Net debt to EBITDA	0.94	0.42	4.96	0.63	0.27
Current ratio	7.55	11.96	58.13	21.66	15.01
Interest coverage	0	0	0	-27.34	0
Income quality	1.12	1.04	0.69	0.73	0.4
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0.15	0.17	0
Capex to operating cash flow	0.01	0	0.04	0.02	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	-1.03	-0.06	-4.51	-5.09	-0.48
Stock based compensation to revenue	0	0	0	0	0
Graham number	18.35	7.95	53.95	36.94	34.57
ROIC	1.67	2.7	0.26	-0.47	-1.06
Return on tangible assets	-0.88	-2.15	-0.2	-0.33	-0.58
Graham Net	3.53	0.96	22.77	7.21	6.5
Working capital	20.16M	6.39M	166.52M	88.81M	80.41M
Tangible asset value	20.44M	6.39M	169.73M	132.4M	102.08M
Net current asset value	20.16M	6.39M	165.52M	82.43M	74.94M
Invested capital	0	0	0	0.04	0.06
Average receivables	0	0	0	317K	317K
Average payables	366K	352K	588.5K	934K	1.27M
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-1.01	-2.35	-0.17	-0.29	-0.65
Capex per share	-0.02	0	-0.12	-0.05	-0.01

Quarterly Fundamentals Overview

Last date of statement is 2022-12-31 for Q4

Metric	2021-12-31	2022-03-31	2022-06-30	2022-09-30	2022-12-31
Revenue per share	0	0	0	0	0
Net income per share	-0.91	-0.96	-0.76	-0.68	-3.46
Operating cash flow per share	-0.61	-0.97	-0.46	-0.47	-0.45
Free cash flow per share	-0.62	-0.98	-0.46	-0.48	-0.45
Cash per share	8.12	7.79	8.75	8.55	7.49
Book value per share	14.41	13.53	12.92	12.35	9.07
Tangible book value per share	11.78	10.91	10.3	9.73	9.07
Share holders equity per share	14.41	13.53	12.92	12.35	9.07
Interest debt per share	0.64	0.66	0.61	0.61	0.57
Market cap	75.84M	57.49M	32.98M	33.35M	30.18M
Enterprise value	47.35M	39.08M	5.98M	-7.55M	12.43M
P/E ratio	-1.85	-1.34	-0.97	-1.08	-0.19
Price to sales ratio	0	0	0	0	0
POCF ratio	-10.98	-5.24	-6.44	-6.24	-6
PFCF ratio	-10.91	-5.24	-6.41	-6.14	-6
P/B Ratio	0.47	0.38	0.23	0.24	0.3
PTB ratio	0.47	0.38	0.23	0.24	0.3
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-4.65	-3.8	-0.7	1.19	-0.31
EV to operating cash flow	-6.86	-3.57	-1.17	1.41	-2.47
EV to free cash flow	-6.81	-3.56	-1.16	1.39	-2.47
Earnings yield	-0.13	-0.19	-0.26	-0.23	-1.29
Free cash flow yield	-0.09	-0.19	-0.16	-0.16	-0.17
Debt to equity	0.07	0.06	0.06	0.07	0.11
Debt to assets	0.06	0.06	0.06	0.06	0.1
Net debt to EBITDA	2.8	1.79	3.18	6.46	0.44
Current ratio	21.66	31.7	28.94	26.59	15.01
Interest coverage	0	-26.52	0	-29.1	0
Income quality	0.68	1.02	0.6	0.7	0.13
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0.17	0.18	0.19	0.2	0
Capex to operating cash flow	0.01	0	0	0.02	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	-0.81	-0.2	-0.38	-0.08	0.01
Stock based compensation to revenue	0	0	0	0	0
Graham number	17.18	17.06	14.85	13.78	26.57
ROIC	-0.1	-0.1	-0.1	-0.15	-0.62
Return on tangible assets	-0.07	-0.08	-0.07	-0.06	-0.34
Graham Net	7.21	7.02	7.91	7.74	6.5
Working capital	88.81M	87.83M	97.6M	94.96M	80.41M
Tangible asset value	132.4M	122.72M	115.94M	109.66M	102.08M
Net current asset value	82.43M	81.67M	91.67M	89.25M	74.94M
Invested capital	0.04	0.05	0.05	0.05	0.06
Average receivables	317K	581K	264K	190K	190K
Average payables	941K	747.5K	466.5K	424K	1.02M
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.06	-0.07	-0.06	-0.06	-0.38
Capex per share	0	0	0	-0.01	0

TARA Frequently Asked Questions

What is Protara Therapeutics, Inc. stock symbol ?

Protara Therapeutics, Inc. is a US stock , located in New york of Ny and trading under the symbol TARA

What is Protara Therapeutics, Inc. stock quote today ?

Protara Therapeutics, Inc. stock price is $3.71 today.

Is Protara Therapeutics, Inc. stock public?

Yes, Protara Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 21.25K
Market Capitalization 39.35M
Employee 31
CEO Mr. Jesse Shefferman
Headquarters New York,NY,US
IPO Date 2014-10-22
Website https://www.protaratx.com

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.